The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Real-world treatment patterns and comparative effectiveness of BTKi in patients with MCL
Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, discusses characterizing real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) via a retrospective multicenter chart review conducted in the Cardinal Health Oncology Provider Extended Network. Electronic medical record data were analyzed on patients with MCL treated with approved BTKis including ibrutinib, acalabrutinib and zanbrutinib from 2018 to 2021. Demographic and clinical characteristics were assessed, as well as MCL baseline features, BTKi treatment patterns, adverse events (AE), and response rates by BTKi. Multivariable regression indicated zanubrutinib demonstrates superior response and favorable AE profile over ibrutinib or acalabrutinib. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
